Beranda › Limfoma Sel B Besar Difus
Uji klinis Limfoma Sel B Besar Difus yang merekrut di AS
100 studi untuk Limfoma Sel B Besar Difus merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- New York City, NY21 studi
- Baldwin Park, CA19 studi
- Chicago, IL18 studi
- Houston, TX17 studi
- Los Angeles, CA17 studi
- Boston, MA16 studi
- Milwaukee, WI16 studi
- Philadelphia, PA15 studi
- Portland, OR15 studi
- Durham, NC14 studi
- Nashville, TN14 studi
- Dallas, TX13 studi
- Salt Lake City, UT12 studi
- Washington, DC12 studi
- Seattle, WA12 studi
- Cincinnati, OH11 studi
- Cleveland, OH11 studi
- Denver, CO11 studi
- Richmond, VA10 studi
- Atlanta, GA10 studi
- Rochester, MN10 studi
- Columbus, OH9 studi
- Cedar Rapids, IA9 studi
- Omaha, NE9 studi
- Edison, NJ9 studi
- Sacramento, CA8 studi
- New Haven, CT8 studi
- St. Louis, MO8 studi
- San Antonio, TX8 studi
- Louisville, KY8 studi
- Jacksonville, FL8 studi
- Greenburgh, NY8 studi
- San Francisco, CA8 studi
- Grand Rapids, MI8 studi
- Miami, FL7 studi
- Indianapolis, IN7 studi
- Aurora, CO7 studi
- Kansas City, MO7 studi
- Charlottesville, VA7 studi
- Pittsburgh, PA6 studi
Berdasarkan negara bagian
- Alabama4 studi
- Arizona13 studi
- Arkansas4 studi
- California42 studi
- Colorado19 studi
- Connecticut8 studi
- Distrik Columbia4 studi
- Florida23 studi
- Georgia15 studi
- Idaho4 studi
- Illinois22 studi
- Indiana9 studi
- Iowa11 studi
- Kansas7 studi
- Kentucky11 studi
- Louisiana6 studi
- Maryland13 studi
- Massachusetts16 studi
- Michigan15 studi
- Minnesota16 studi
- Missouri8 studi
- Montana4 studi
- Nebraska9 studi
- Nevada3 studi
- New Jersey13 studi
- New Mexico3 studi
- New York31 studi
- North Carolina20 studi
- North Dakota4 studi
- Ohio23 studi
- Oklahoma5 studi
- Oregon15 studi
- Pennsylvania19 studi
- South Carolina4 studi
- South Dakota3 studi
- Tennessee18 studi
- Texas29 studi
- Utah14 studi
- Virginia17 studi
- Washington17 studi
- Wisconsin19 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06649812Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Menerima pesertaStudi observasional
Usia 0 hingga 38 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06131801Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Menerima pesertaFase 2
Usia 65 hingga 99 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT05952024Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06977711Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT03418038Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Menerima pesertaFase 1/2
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT03223610A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06890884A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07519772A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05139017A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06091865A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06717347Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06784167A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Menerima pesertaFase 1/2
6 Months – 25 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06395103Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT05757219Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04002947A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06806033Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT05272384Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07225439Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT06500273Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07284433CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT06687772Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.